UY35441A - Agentes quelantes de precursores de producto final de glicación avanzada (age). - Google Patents

Agentes quelantes de precursores de producto final de glicación avanzada (age).

Info

Publication number
UY35441A
UY35441A UY0001035441A UY35441A UY35441A UY 35441 A UY35441 A UY 35441A UY 0001035441 A UY0001035441 A UY 0001035441A UY 35441 A UY35441 A UY 35441A UY 35441 A UY35441 A UY 35441A
Authority
UY
Uruguay
Prior art keywords
age
precursors
glication
advanced
final product
Prior art date
Application number
UY0001035441A
Other languages
English (en)
Spanish (es)
Inventor
Besev Magnus
Robert J Miller
S Randall Holmes-Farley
Dhal Pradeep
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of UY35441A publication Critical patent/UY35441A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UY0001035441A 2013-03-15 2014-03-14 Agentes quelantes de precursores de producto final de glicación avanzada (age). UY35441A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
UY35441A true UY35441A (es) 2014-10-31

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035441A UY35441A (es) 2013-03-15 2014-03-14 Agentes quelantes de precursores de producto final de glicación avanzada (age).

Country Status (24)

Country Link
US (2) US20160024233A1 (enExample)
EP (1) EP2968403A1 (enExample)
JP (4) JP2016512830A (enExample)
KR (1) KR20150130492A (enExample)
CN (1) CN105188718A (enExample)
AR (1) AR095593A1 (enExample)
AU (2) AU2014235500A1 (enExample)
BR (1) BR112015023404A8 (enExample)
CA (1) CA2906501A1 (enExample)
CL (1) CL2015002624A1 (enExample)
CR (1) CR20150545A (enExample)
DO (1) DOP2015000221A (enExample)
EA (1) EA201591733A1 (enExample)
HK (1) HK1220607A1 (enExample)
IL (1) IL241406A0 (enExample)
MA (1) MA38487A1 (enExample)
MX (1) MX2015012843A (enExample)
PE (1) PE20151766A1 (enExample)
PH (1) PH12015502019A1 (enExample)
SG (2) SG10201707590XA (enExample)
TN (1) TN2015000390A1 (enExample)
TW (1) TW201521744A (enExample)
UY (1) UY35441A (enExample)
WO (1) WO2014150873A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
EP3675737A4 (en) * 2017-08-31 2021-02-17 Cytosorbents Corporation REDUCTION OF ADVANCED GLYCATION END PRODUCTS FROM BODY FLUIDS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
AU2002257145B2 (en) * 2001-04-18 2005-06-02 Genzyme Corporation Method for lowering serum glucose
WO2005032563A1 (en) * 2003-09-02 2005-04-14 Genzyme Corporation Method for reducing vascular inflammation
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
AU2005214971A1 (en) * 2004-02-17 2005-09-01 Dynamis Therapeutics, Inc. Fructoseamine 3 kinase and the formation of collagen and elastin
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
CN105017481B (zh) * 2010-02-24 2018-10-02 瑞立普萨公司 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺

Also Published As

Publication number Publication date
JP2018135365A (ja) 2018-08-30
IL241406A0 (en) 2015-11-30
AU2019201259A1 (en) 2019-03-14
BR112015023404A2 (pt) 2017-07-18
DOP2015000221A (es) 2015-12-15
TN2015000390A1 (en) 2017-01-03
TW201521744A (zh) 2015-06-16
US20180265613A1 (en) 2018-09-20
CA2906501A1 (en) 2014-09-25
EP2968403A1 (en) 2016-01-20
WO2014150873A1 (en) 2014-09-25
CL2015002624A1 (es) 2016-03-11
MA38487A1 (fr) 2017-12-29
EA201591733A1 (ru) 2016-01-29
AU2014235500A1 (en) 2015-11-05
CN105188718A (zh) 2015-12-23
BR112015023404A8 (pt) 2019-12-03
JP2016512830A (ja) 2016-05-09
JP2020055850A (ja) 2020-04-09
CR20150545A (es) 2015-12-01
AR095593A1 (es) 2015-10-28
PE20151766A1 (es) 2015-12-11
SG11201506413PA (en) 2015-09-29
KR20150130492A (ko) 2015-11-23
SG10201707590XA (en) 2017-11-29
PH12015502019A1 (en) 2016-01-11
MX2015012843A (es) 2016-08-08
US20160024233A1 (en) 2016-01-28
HK1220607A1 (zh) 2017-05-12
JP2022037143A (ja) 2022-03-08

Similar Documents

Publication Publication Date Title
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
MX2018013099A (es) Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5- il)-piridin-3-il)metoxi)benzaldehido.
EA201890201A1 (ru) Антибактериальные соединения
TW201613901A (en) New compounds
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
GT201500051A (es) Inhibidores de glucosilceramida sintasa
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
TN2015000278A1 (en) Autotaxin inhibitors
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
EA201400178A1 (ru) Лечение рака молочной железы
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY34859A (es) Análogos peptídicos de la exendina 4.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
PE20151746A1 (es) Compuestos biciclicos
GEP201606566B (en) Isoxazolidine derivatives
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
PH12017501695A1 (en) Treatment of type 2 diabetes mellitus patients
UY35441A (es) Agentes quelantes de precursores de producto final de glicación avanzada (age).
EA201690938A1 (ru) Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
EA201401045A1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
CY1118614T1 (el) Νεα παραγωγα (αζα)βενζυδρυλαιθερα, διεργασια παρασκευης τους και χρηση τους ως προσδετες h4-υποδοχεα για θεραπευτικες εφαρμογες

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211112